<DOC>
	<DOC>NCT02919579</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the effect of a single 84-milligram (mg) dose of intranasal esketamine compared to placebo, on next day driving performance and repeated administration of 84 mg intranasal esketamine on same-day driving performance as assessed by the mean difference of standard deviation of lateral position (SDLP) from an on-road driving test.</brief_summary>
	<brief_title>A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<criteria>Willing and able to adhere to the prohibitions and restrictions specified in this protocol If a woman, must have a negative serum beta human chorionic gonadotropin pregnancy test at screening and a negative urine pregnancy test on Day 1 of Period 1 in Part A and prior to study drug administration in Part B Comfortable with selfadministration of intranasal medication and able to follow instructions provided Normal visual acuity (corrected or uncorrected) Based on selfreport, able to consume an amount of alcohol that typically produces a blood alcohol concentration (BAC) of 0.05 percent (that is, 2 to 3 alcoholic drinks ingested within 2 hours on a single occasion) Current or prior diagnosis of psychosis/psychotic or bipolar disorder Primary sleep disorder, such as insomnia, requiring pharmacological intervention at Screening Clinically significant abnormal values for hematology, clinical chemistry, or urinalysis at screening or Day 1 of Period 1 as deemed appropriate by the investigator Clinically significant abnormal physical examination, vital signs, or 12lead electrocardiogram (ECG) at screening or Day 1 of Period 1 as deemed appropriate by the investigator History of moderate or severe use disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSMIV or DSM5) criteria within 1 year before screening or positive test result(s) for alcohol and/or drugs of abuse (such as barbiturates, opiates, cocaine, cannabinoids, amphetamines, and benzodiazepines) at screening and Day 1 of Period 1</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>